“体检十年未查出患癌风险” 防癌的相关体检还靠谱吗？

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has emerged after a lawyer, Zhang Xiaoling, claimed that her ten years of health check reports showed no cancer risk, yet she was later diagnosed with late-stage kidney cancer. This raises questions about the reliability of routine health checks and cancer screening methods [2][3][8]. Group 1: Company Response - Aikang Guobin has conducted internal reviews and external expert evaluations, asserting that they bear no responsibility for the alleged oversight in Zhang's health checks and are open to third-party assessments [11][18]. - The company stated that Zhang's 2023 report indicated a "right kidney calcification focus" and a "possible left kidney hamartoma," contradicting her claims of no abnormalities [8][11]. - Aikang emphasized that cancer detection is a complex process influenced by various factors, including the timing of tests and the methods used, and that some cancers may not be detectable at certain stages [19][20]. Group 2: Industry Insights - The cancer screening industry is evolving, with a projected market size of $20.82 billion in 2022, expected to reach $28.93 billion in 2023, highlighting the growing demand for effective early detection methods [26][27]. - Current cancer screening technologies primarily include X-rays, CT scans, MRI scans, and ultrasound, while advanced techniques like liquid biopsies and AI-assisted imaging are being developed [27]. - Experts recommend that individuals over 40 should undergo annual ultrasound checks for urinary system cancers, as conventional blood tests may not reliably indicate kidney cancer risk [20][21].